e for Initiation of Clinical Trials
Selected Abstract
Human Genome Sciences Receives Milestone Payment From GlaxoSmithKline for Initiation of Clinical Trials of Second Genomics-Derived Drug for Cardiovascular Disease; - Third Small Molecule Drug Arising from the Human Genome Sciences- GlaxoSmithKline Agreement to Enter Clinical Trials -.
Human Genome Sciences, Inc. announced today that it has received a clinical milestone payment from its partner, GlaxoSmithKline, related to the initiation of human clinical trials of a second lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, 659032. Lp-PLA2 is an enzyme associated with ... February 27, 2003; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles No Results Found.
|
